Egen, Inc.
Records under this name other than patents Egen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,964,571 | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,144,546 | Nucleic acid-lipopolymer compositions Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,827,331 | Nucleic acid-lipopolymer compositions Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,900,621 | Polyamine derivatives Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,932,638 | Polyamine Derivatives Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,254,334 | Polyamine derivatives Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,569,065 | Compositions and methods for the delivery of biologically active RNAs Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,460,696 | Polyamine derivatives Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,468,687 | Immuno gene therapy for treatment of cancer and hyperproliferative diseases Formerly held Term ended Term ended Feb 7, 2026 · From the USPTO record | Term ended | Term ended Feb 7, 2026 | From the USPTO record |
| US 8,623,837 | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases Formerly held Term ended Term ended Dec 24, 2025 · From the USPTO record | Term ended | Term ended Dec 24, 2025 | From the USPTO record |